KRAS Wild Type
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma (NCT01351038) | Arbeitsgemeinschaft medikamentoese Tumortherapie |
Track KRAS Wild Type automatically
Every clearance here is in the API, with alerts when new ones post.